Prostate Cancer
Conditions
Keywords
Prostate Cancer
Brief summary
Flotufolastat F-18 Injection is a positron emission tomography (PET) imaging tracer that targets the extracellular domain of prostate-specific membrane antigen (PSMA). This phase I study investigated the safety, biodistribution, radiation dosimetry and Pharmacokinetics of Flotufolastat F-18 Injection in 6 healthy elderly Chinese volunteers.
Detailed description
Flotufolastat F-18 Injection is a positron emission tomography (PET) imaging tracer that targets the extracellular domain of prostate-specific membrane antigen (PSMA). It is intended for the detection of prostate cancer (PCa) lesions.This Phase I study will be open-labeled, nonrandomized, single center study. Enrolled 6 healthy Chinese volunteers who meet all of the inclusion and none of the exclusion criteria. Subjects will receive 5.47\ 6.69mCi of Flotufolastat F-18 Injection via IV injection. Safety and tolerability will be observed. Biodistribution, pharmacokinetics, and dosimetry will be investigated.
Interventions
Single dose intravenous injection of Flotufolastat F-18 Injection . Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
Sponsors
Sinotau Pharmaceutical Group
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Have the ability to understand the content of study and voluntarily sign the informed consent form. 2. Healthy male or female, aged 18-60 (included). 3. Body mass index (BMI) between 19 and 26 kg/m² (included). 4. Vital signs, physical examination, 12-lead electrocardiogram (ECG), chest X-ray (posterior-anterior view), and abdominal ultrasound are normal, or any abnormalities that are diagnosed clinically insignificant. 5. Clinical laboratory test results are within normal ranges or any abnormalities that are diagnosed clinically insignificant. 6. Have the ability to communicate effectively with the investigator and comply with the study requirement to follow-up. 7. Female subject shouldcontracept effectively during the study period and 6 months after the study completed (effective contraception includes sterilization, intrauterine hormonal devices, condoms, contraceptive pills/agents, abstinence, or partner vasectomy). Male subject should agree to use contraception during the study period and 6 months after the study completed.
Exclusion criteria
1. Claustrophobia or inability to tolerate imaging examinations for any other reason. 2. Have a history of epilepsy or seizures, excluding childhood febrile seizures. 3. With chronic diseases, including but not limited to: 1. cardiovascular, respiratory, gastrointestinal, urinary, hematological disease, neurological, endocrine, metabolic, or musculoskeletal diseases, or a history thereof. 2. history of psychiatric disorders or currently significant psychiatric conditions 4. Have a history of asthma or allergies. 5. Have a history of malignant tumors. 6. Present any condition that may interfere with the absorption or metabolism of the investigational drug, or that may affect study results, as determined by the investigator to be clinically significant. 7. Underwent any surgical procedure within 3 months before administration or planned surgery during the study period. 8. Accomplished the blood donation or significant blood loss (\>400 mL) within 3 months before administration or during the screening period. 9. Insufficient venous access (two distinct venous lines are required for investigational drug administration and PK sampling). 10. Known allergy to the active ingredient or any excipients of the investigational product. 11. Took any medications, including prescription, over-the-counter drugs, or herbal remedies, within 14 days before administration. 12. Participated any other new drug's clinical trial within 4 weeks prior to the administration or within 5 half-lives of the investigating drug (whichever is longer). 13. Radiopharmaceutical imaging or treatment within 7 days prior to screening or within 5 half-lives of the radiopharmaceutical (whichever is longer). 14. Pregnant or breastfeeding women. 15. Abnormal serological results (hepatitis B surface antigen, syphilis treponemal antibody, human immunodeficiency virus antibody, hepatitis C antibody) diagnosed clinically significant by the investigator. 16. QTc intervalis longer than 450 milliseconds during the screening period. 17. Major occupational exposure to ionizing radiation in the past 10 years (e.g., more than 50 mSv/year) or exposure to radioactive materials or ionizing radiation for therapeutic or research purposes. 18. Any reason determined by the investigator that could not complet the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the biodistribution of Flotufolastat F-18 Injection after a single bolus intravenous injection in healthy Chinese adults. (%ID) | Day 1 | Radioactive accumulation (%ID) in target organs following administration of Flotufolastat F-18 Injection. |
| To evaluate the biodistribution of Flotufolastat F-18 Injection after a single bolus intravenous injection in healthy Chinese adults. | Day 1 | Standardized uptake value (SUV) in target organs following administration of Flotufolastat F-18 Injection. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To assess the radiation dosimetry of Flotufolastat F-18 Injection | Day 1 | Radiation dose in target organs and whole-body effective dose following administration of Flotufolastat F-18 Injection |
| To evaluate the pharmacokinetic of Flotufolastat F-18 Injection | Day 1 | Radioactivity concentration (%ID/g) in whole blood, plasma, and urine samples at various time points post Flotufolastat F-18 Injection, and associated time activity curves. |
| Proportions of radioactive parent compound in plasma | Day 1 | To evaluate the pharmacokinetic of Flotufolastat F-18 Injection |
| To evaluate the safety profile of Flotufolastat F-18 Injection | Day 2 | Types, severity, incidence, and outcomes of adverse events (AEs) and serious adverse events (SAEs) reported during the study period |
Countries
China
Contacts
Primary ContactRuimin Wang, Doctor
Outcome results
None listed